☆ 4.6 Letter

Characterization of patients with advanced basal cell carcinoma progressing while receiving Hedgehog pathway inhibitors

BRITISH JOURNAL OF DERMATOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Dermatology

Predictive Factors of Non-Response to Vismodegib in Locally Advanced Basal-Cell Carcinoma

Helene Marescassier et al.

Summary: In a retrospective multicenter study, factors associated with non-response to vismodegib in patients with locally advanced basal cell carcinomas (laBCC) were identified. Muscle involvement, history of radiotherapy, and intermittent use of vismodegib were significantly associated with non-response. Further studies are needed to confirm these findings due to the limited sample size.

DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study

R. Dummer et al.

BRITISH JOURNAL OF DERMATOLOGY (2020)

Add to Collection

Article Dermatology

Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial

Scott W. Fosko et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

Article Dermatology

Basal cell carcinoma Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations

Michael C. Cameron et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Add to Collection

Article Oncology

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

Aleksandar Sekulic et al.

BMC CANCER (2017)

Add to Collection

Article Dermatology

The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma

Reinhard Dummer et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)

Add to Collection

Article Dermatology

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC

Aleksandar Sekulic et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)

Add to Collection

Article Oncology

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

Michael R. Migden et al.

LANCET ONCOLOGY (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.